Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | CSK | P41240 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734506 | 0.89 | AURKA (0.56) | AURKAAURKBEGFRIGF1RFGFR1 | |
| SCHEMBL14595004 | 0.89 | AURKA (0.45) | AURKAAURKBEGFRIGF1RFGFR1 | |
| SCHEMBL12152944 | 0.87 | MET (0.43) | AURKAAURKBKDRMET | |
| SCHEMBL1734667 | 0.85 | AURKB (0.71) | AURKAAURKBEGFRIGF1RFGFR1 | |
| SCHEMBL1733752 | 0.82 | AURKB (0.66) | AURKAAURKBEGFRIGF1RFGFR1 | |
| SCHEMBL1942943 | 0.81 | AURKB (0.57) | AURKAAURKBEGFRIGF1RFGFR1 | |
| SCHEMBL14627857 | 0.81 | AURKB (0.48) | AURKAAURKBEGFRIGF1RFGFR1 | |
| SCHEMBL1940774 | 0.79 | AURKA (0.51) | AURKAAURKBEGFRIGF1RFGFR1 | |
| SCHEMBL1734664 | 0.79 | AURKB (0.61) | AURKAAURKBEGFRIGF1RFGFR1 | |
| SCHEMBL1734484 | 0.79 | AURKB (0.62) | AURKAAURKBEGFRIGF1RFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899345-B1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-1899345-B1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-16 | — | — | EP | disclosed |
| US-7402582-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402582-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402582-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2007005630-A1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004732-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004732-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004732-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004732-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | MAP3K20, PRKDC, MAP3K2 | AURKA 499/4885AURKB 342/4885EGFR 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.